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Head and neck squamous cell carcinoma (HNSCC) is a type of cancer that begins in the
epithelial cells that line the mucosal surfaces of the head and neck, including the oral cavity,
pharynx, larynx, paranasal sinuses, nasal cavity, and salivary glands. Head and neck cancer is
the sixth most common type of cancer with a 5-year survival rate of 60% for all cases. Over the
past few years, a subset of cells with stem-like properties, called cancer stem cells, are believed
to have tumor-initiation capabilities and are responsible for maintaining on-going tumor growth.
Previous data from our lab suggested that cells grown in suspension, called spheroids, may have
stem cell like properties.
We employed a model system where a primary HNSCC cell line, HN4, was used to set
up spheroids. We found that expression of EPS8 and its downstream targets, FOXM1 and
CXCL5, was increased in HN4 spheroids. In addition, we measured the expression of Nanog, as
it is a transcription factor involved in the self-renewal of human embryonic stem cells. We also

used a metastatic HNSCC cell line, HN12, to see how it compared to spheroids. We wanted to
investigate the hypothesis that activation of Src potentiates EPS8 function to deregulate
downstream signaling pathways. We used a small molecule tyrosine kinase inhibitor, Dasatinib,
on HN4 spheroids and HN12 cells. We found that when Src is inhibited, EPS8 expression is
decreased in HN4 spheroids and it also interferes with spheroid formation. The results of the
current study were also able to show that the proliferation capability of HN12 cells is greatly
diminished when treated with Dasatinib, due to G1 arrest in the cell cycle. When we measured
for FOXM1, which is a cell cycle regulator, we found the levels were reduced in Dasatinib
treated cells, preventing the cells from completing mitosis. With all of the data taken together, it
suggests that Src does in fact play a role in regulating the downstream signaling pathways of
EPS8, and its inhibition leads to the loss of cell proliferation. Additional studies need to be
performed to discover whether Src inhibition will stop the proliferation of cancer stem cells,
which are believed to be more resistant to cytotoxic therapies.

1. Introduction and Background

1.1 Head and Neck Squamous Cell Carcinoma (HNSCC)
Head and Neck Squamous Cell Carcinoma (HNSCC) is a type of cancer that begins in
the epithelial cells that line the mucosal surfaces of the head and neck, including the oral cavity,
pharynx, larynx, paranasal sinuses, nasal cavity, and salivary glands (1). Head and neck cancer
is the sixth most common type of cancer, accounting for 3% of all cases (1). In the past two
decades, there has been a slight decrease in the overall incidence of HNSCC (2). About one third
of all patients diagnosed with HNSCC are Stage I or Stage II. Treatment options involve
radiation therapy or surgery and are usually based on primary tumor location and patient
preference. With stage I disease, the survival rate is up to 90% and with stage II disease, the
survival rate is about 70% (2). About two thirds of patients are diagnosed with advanced stage
disease, Stage III or Stage IV, which commonly involves the lymph nodes. The main forms of
curative management are surgery, radiotherapy, and chemotherapy (2). The 5-year survival rate
for all stages based on Surveillance Epidemiology and End Results (SEER) is 60% (2).
The two most important risk factors for HNSCC are alcohol and tobacco consumption
(2). When consumed together, they have a multiplicative effect due to a possible synergist
relationship (2,3). Tobacco smoking, including passive smoking, is a major risk for HNSCC due
to the genotoxic effects of carcinogens in tobacco smoke, including nitrosamine and polycyclic
hydrocarbons (4). By itself, alcohol is not a primary carcinogen, but acetaldehyde, a metabolite
of ethanol, is a direct carcinogen (3,4). Acetaldehyde forms DNA adducts that interfere with
DNA synthesis and repair (4). A possible explanation for why alcohol potentiates the effects of
tobacco is due to its nature as a chemical solvent, which enhances and prolongs mucosal
1

exposure to the carcinogens present in tobacco (4). Another risk factor for HNSCC, particularly
in the younger generation, is infection with human papillomavirus (HPV), mainly HPV-16 (2).
HPV infection is not related to alcohol or tobacco consumption and occurs most frequently in
non-smokers and non-drinkers (2). It mediates its carcinogenic effect through E6 and E7 viral
oncoproteins, which inactivate the tumor suppressor proteins p53 and pRb, respectively (2).

1.2 Cancer Stem Cells
Over the past few years, scientists have proposed that many different cancers, including
HNSCC, contain a subset of cells that appear to have stem-like properties (6). This subpopulation of tumor cells has the ability for self-renewal and differentiation, similar to normal
stem cells. These cells are referred to as cancer stem cells (CSCs), and have tumor-initiation
capabilities and the ability to maintain on-going tumor growth (5, 6). They are believed to have
increased resistance to standard cytotoxic therapies and are a major reason for tumor recurrence
(5, 6).
Tumors have generally been considered to be homogenous, which means that every
cancer cell has an equal tendency to initiate and spread tumors (1). The heterogeneity in tumor
cells was believed to be due to the stochastic accumulations of several varied mutations (6). The
microenvironment is also responsible for sending signals that provide a selective advantage to
some tumor cells (6). Due to developing evidence about the cancer stem cell hypothesis, it is
now believed that there is a distinct hierarchy of cells in tumor tissue. The majority of the tumor
consists of rapidly proliferating cells, known as transit amplifying cells in normal tissue, which
do not contribute to tumor initiation. CSCs are capable of asymmetric division, giving rise to the
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diverse population of differentiated progenitor cells that make up a heterogeneous tumor (1, 6,
7).
Many studies have exhibited that cells growing in suspension contain stem cell properties
(5). A previous study by our lab showed that cell lines derived from HNSCC contain putative
CSCs that can grow three-dimensionally as spheroids (squamospheres) (W.A. Yeudall,
unpublished data).

1.3 Cell Surface Markers
Cancer stem cells are thought to play an important role in tumor initiation and
progression. There are several markers that are used for the isolation of CSCs in solid tumors.
CD44+/CD24- for breast cancer, CD133+ for brain tumors and colon cancer, and CD44+ for
gastric cancer have been reported (8). These markers, however, are not selective for the reported
cancers only. Some of the markers that are shared across malignancies are CD20, CD24, CD34,
CD44, CD90, CD117, CD133, CD166, and EpCAM (9). Some proteins, such as EpCam
(Epithelial Cell Adhesion Molecule, CD326) and CD44, are expressed in an ubiquitous way on
most carcinoma cells (9).
EpCAM is identified as a marker for pluripotency and proliferation in human and murine
embryonic stem cells. EpCAM is a type I transmembrane glycoprotein consisting of a large
extracellular domain, a single transmembrane domain, and a short intracellular cytoplasmic tail
(9, 10). The extracellular domain contains an epidermal growth factor (EGF)-like domain and a
putative thyroglobulin (TY) domain (10). N-glycosylation of the membrane-proximal
asparagine198 in tumor cells resulted in a 3-fold increase in the half-life of EpCAM. This is of
interest as EpCAM was shown to be hyperglycosylated in the majority of head and neck
carcinomas when compared to normal mucosa (9).
3

CD44 is a cell surface glycoprotein that is thought to stimulate cancer growth and
metastasis through multiple mechanisms (6). It is a receptor for hyaluronic acid and it also
interacts with ligands such as matrix metalloproteases (6). CD44 is involved in cell-cell
adhesion, cell-matrix adhesion, endothelial attachment and invasion, cell signal transmission, and
cell proliferation (7). Due to its role in regulation of growth, differentiation, and migration, it is
thought to be involved with tumor progression and metastasis (12). CD44+ cancer cells were
found to be tumorigenic when injected into immunodeficient mice, showing they are capable of
tumor initiation, whereas CD44- failed to form tumors (5).

1.4 EGFR Signaling
Epidermal growth factor receptor (EGFR) is a 170kD glycoprotein belonging to a family
of receptor tyrosine kinases (RTKs) that is involved in the regulation of epithelial cell
proliferation. The ErbB family of receptors includes EGFR (ErbB-1/Her1), ErbB-2 (Her2),
ErbB-3 (Her3), and ErbB-4 (Her4). Due to being structurally related, the ErbB family forms an
integrated system which often leads to a signal being transmitted to the other receptors of the
family and eventually giving rise to signal amplification and diversification (13). Although
EGFR is known for its role in epithelial cell proliferation, aberrant activity of the receptor or its
downstream pathways is associated with the development of squamous cell carcinoma (14). High
levels of EGFR are associated with increased production of transforming growth factor alpha
(TGFα). Secretion of TGFα leads to autocrine (self) stimulation or paracrine stimulation (of
other cells) (15).
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EGFR is comprised of an extracellular ligand binding domain, a hydrophobic
transmembrane domain, and a tyrosine-kinase containing intracellular domain. The receptor is
activated by binding to ligands of the EGF-like family of growth factors, including EGF, TGFα,
and HB-EGF, which causes homo- or hetero- dimerization of receptors, and subsequent
activation of the intrinsic receptor tyrosine kinase (15). This causes auto- and transphosphorylation of the receptors and several other cellular substrates (16). Proteins that contain a
src-homology 2 (SH2) domain bind to the phosphotyrosine residues on the receptor and initiate
multiple signal transduction pathways, which control cellular proliferation. EGFR signaling is
now considered an important regulator of cellular motility, facilitating tumor progression. It acts
through many downstream mediators, which include phospholipase C-gamma, extracellular
signal-regulated kinase (ERK), focal adhesion kinase (FAK), and integrin subunits (14).

1.5 EPS8
EGFR pathway substrate 8 (EPS8) is a 97kDa protein that is a substrate for RTKs,
including EGFR, platelet derived growth factor receptor (PDGFR), and fibroblast growth factor
receptor (FGFR) (17). There are two isoforms of EPS8, p97EPS8 and p68EPS8. The p97EPS8
isoform is the one commonly found in human cancer cells (18). EPS8 contains a split pleckstrin
homology (PH) domain, a Src homology domain (SH3), and proline-rich regions (18). The SH3
domain of EPS8 interacts with Shc, RN-tre, Abi-1 (E3B1), and Irsp53 (19), while the prolinerich sequences of EPS8 directly bind to the SH3 domain of Src (18). The C-terminal effector
domain of EPS8 is where actin capping and bundling occurs and this is mediated by the binding
of EPS8 to Abi-1 (17). EPS8 forms a complex with Abi-1 and guanine nucleotide exchange
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factor son-of-sevenless-1 (SOS-1), which is important for transmitting signals to Rac from RTKs
and phosphoinositide-3-kinase (PI3K) and resulting in actin remodeling and cell motility (14).
EPS8 enhances mitogenic signaling and the p97EPS8 isoform is shown to be constitutively
tyrosine phosphorylated in many cancer cell lines (19). Cells overexpressing EPS8 induced a
cohort of genes whose products led to cell cycle progression and mitotic spindle function (19).
Because of its role in actin remodeling and actin-based mobility, it has been linked to
proliferation and migration (18).

1.6 Nanog
Nanog is a homeodomain transcription factor, along with OCT4 and SOX2, that
maintains pluripotency and self-renewal of human embryonic stem cells (20). High expression
of Nanog is an indicator of poor prognosis for many cancers, including colorectal and breast
cancer, prostate cancer, and ovarian serous carcinoma (20). After looking at effects of Nanog on
other cancers, the effects of Nanog on HNSCC was of great interest. Nanog mRNA and protein
levels were greater in oral squamous cell carcinoma cell lines compared to normal oral epithelial
cell lines (21). Through other recent studies, it has been implicated that Nanog helps in the
regulation of cancer stem cells. HNSCC CSCs have been shown to have higher levels of Nanog
expression and are associated with an EMT phenotype (20). Studies that knocked down Nanog
showed the loss of HNSCC CSC's spheroid-forming capabilities and their invasive properties
(21).
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1.7 FOXM1
Forkhead box protein M1 (FOXM1) is a transcription factor that contains a DNA-binding
domain called the winged helix or forkhead box domain (22). The protein plays a key role in the
maintenance of homeostasis between cell proliferation and apoptosis; therefore, alterations in
FOXM1 expression are associated with carcinogenesis (22). There are three alternatively spliced
isoforms of FOXM1, out of which FOXM1B is the key isoform associated with oncogenesis
(23). It is overexpressed in various human cancers, including HNSCC (23). High expression of
FOXM1 is positively correlated with the incidence of metastases and inversely correlated with
patient survival times (23). FOXM1 is also a key cell cycle regulator that is important for the
transition from G1 to S phase and for progression throughout mitosis (22). It regulates the
transcription of genes involved in the cell cycle, such as Aurora B Kinase, Cdc25B, survivin,
CENPA, and CENPB (25).
According to a previous study, FOXM1 was one of the gene products that was elevated in
the presence of EPS8, along with a cohort of FOXM1 cell-cycle related targets (24). With
knockdown of EPS8 in HN12 cells, which have high levels of endogenous EPS8, FOXM1
protein levels were reduced (24). HN4 cells, which have low endogenous levels of EPS8,
transfected with FOXM1 had a similar proliferation rate compared to HN4 cells transfected with
EPS8, suggesting that FOXM1 potentially mediates the proliferative effects of EPS8 on cellular
growth (24). With the presence of EPS8, FOXM1 promoter activity was increased in SVpgC2a
immortalized buccal keratinocytes and 293-T cells, suggesting that EPS8 mediates the
transactivation of the FOXM1 promoter (24).
FOXM1 is upregulated during tissue regeneration in response to injury, which suggests
that it is a signal that is required for the enlargement of progenitor/regenerative stem cells for
7

replenishing the epithelium (23). The aberrant upregulation of FOXM1 in cancer cells may alter
the balance between progenitor cell expansion and terminal differentiation, which agrees with
the cancer stem cell hypothesis that a subpopulation of cells are responsible for tumor initiation
and self-renewal (23).

1.8 Chemokines
Chemokines belong to a family of small (8-10 kDa) homeostatic cytokines that function
as immune chemoattractants and/or lymphocyte activators (26). They stimulate the migration of
many different types of cells, which include lymphocytes, endothelial cells, mesenchymal stem
cells, and malignant epithelial cells (27). Chemokines can be divided into four groups, depending
on the location and number of the N-terminal cysteine residue, CXC-, CC-, C-, and CX3Cchemokines (26, 27). CXC- chemokines have a single amino acid residue (X) in between the first
N-terminal cysteine residues (C) (27). Chemokine receptors are classified by the type of ligands
they bind. For example, CXC- receptors bind CXC- ligands (27).
Chemokines bind to their specific receptors on target cells to induce signaling (26).
Chemokine receptors belong to the family of G protein-coupled receptors (GPCRs), which
usually contains an extracellular ligand-binding domain, seven transmembrane α-helix domains,
and an intracellular carboxyl terminus (26, 27). One of the intracellular loops of the
transmembrane domain interacts with the heterotrimeric G proteins (Gα, Gβ, and Gγ), which
mediate downstream signaling upon ligand binding. When activated, the GPCR acts as a guanine
nucleotide exchange factor (GEF) and causes the GDP to be replaced with GTP on Gα. This
causes the G protein to be released from the receptor and the dissociation of the Gα subunit from
the Gβ/γ dimer (27). Both of these activated complexes interact with several target proteins,
8

including Ras, ERK, PI3K, and the small GTPases Rho, Rac, and cdc42 (26 ,28). These
intermediates are related to pathways regulating actin reorganization and cellular motility;
therefore, chemokines are said to play a role in the regulation of cell migration (26, 28). PI3K
activation due to GPCR signaling leads to the activation of focal adhesion kinase, eliciting a
migratory response in different cells, including tumor cells (27).
It is considered that tumor cells use chemokine-dependent mechanisms for migrating to
specific secondary sites (28). One chemokine of interest is CXCL5, which binds to CXCR2 (26,
28). According to a previous study, CXCL5 is found overexpressed in a metastasized HNSCC
cell line compared to a primary HNSCC cell line (28). Inhibition of CXCL5, using RNAi,
showed a 9-fold decrease in cell migration in metastatic HNSCC cells, indicating that CXCL5
plays a key role in cell migration and invasion. Inhibition of CXCL5 has also been shown to
decrease cell proliferation (28). EPS8 was also shown to upregulate expression of CXCL5, in a
FOXM1 dependent manner (19). This phenomenon can be explained by EPS8 enhancing the
expression of FOXM1, which activates transcription from the CXCL5 promoter; however, it is
not known whether enhanced chemokine expression is due to direct binding of FOXM1 to the
CXCL5 promoter (19).
CXCL12 (ligand stromal-derived factor-1, SDF-1) is a chemokine that is involved in
tumor growth and angiogenesis (29). It is able to bind to the receptors CXCR4 and CXCR7;
although, the CXCL12/CXCR7 system does not lead to activation of typical G protein signaling
pathways (27). CXCR4 signaling via tyrosine kinases, such as Src, leads to the transcription of
genes involved in cell cycle progression, cell migration, and survival (29). The stromal
fibroblasts found in carcinomas, carcinoma-associated fibroblasts (CAFs), mediate angiogenesis
and matrix degradation due to elevated secretion of CXCL12 and matrix-metalloproteinase-1
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(MMP-1) (27). It has been shown that CAF-mediated CXCL12 causes epithelial-tomesenchymal transition (EMT) in primary tumors (27). According to one study,
CXCL12/CXCR4 mediated signaling through PI3K/AKT is essential in the self-renewal of
prostate cancer cells with a stem cell phenotype (27). With growing evidence, CXCL12/CXCR4
is associated with tumor invasion, progression, angiogenesis and lower patient survival due to
resistance to therapeutics (29).

1.9 Tyrosine Kinase
Tyrosine kinases are enzymes that transfer the ϒ-phosphate from ATP to the hydroxyl
group of tyrosine residues on signal transduction molecules, leading to their activation (30).
Tyrosine kinases play a key role in signal transduction by acting as relay points for a network of
interdependent signaling molecules (30). It is common for tyrosine kinase activity to be
dysregulated in tumor cells, with excessive phosphorylation keeping signal transduction
pathways in an activated state. Receptor tyrosine kinases (RTKs) transduce signals from both
inside and outside the cell (30). They are transmembrane glycoproteins that become active with
ligand-binding, and they transduce the extracellular signal to the cytoplasm by phosphorylating
tyrosine residues on the receptor itself, called autophosphorylation, or on other signaling proteins
(31). Another family of tyrosine kinases are non-receptor tyrosine kinases (NRTKs), which lack
a transmembrane domain and are found in the cytoplasm (30).
The largest subfamily of NRTKs is the Src family, which includes nine members that
share similar structure and function (32, 33). Src family kinases (SFKs) have a conserved domain
structure that consists of SH1 (tyrosine kinase) domain, SH2, and SH3 domain (32). SFKs are
critical for cell adhesion, invasion, proliferation, and survival during tumor development (33).
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They are important mediators in many signaling pathways that are involved in oncogenesis and
their overexpression occurs frequently in tumor tissues (33). SFKs can interact with tyrosine
kinase receptors, for example EGFR, and they represent a promising target to inhibit tumor
growth (33).
Dasatinib is a small molecule tyrosine kinase inhibitor that targets BCR-ABL, and is
clinically approved for the treatment of chronic myeloid leukemia (34). Besides BCR-ABL, it
also has the ability to inhibit the kinase activity of many RTKs and NRTKs, such as the SFKs
(35,36). Dasatinib is able to bind to the kinases, inhibiting their autophosphorylation, and
subsequent downstream phosphorylation of additional targets, therefore, halting downstream
pathways (36).

1.10 Model System
For our model system, we used primary HNSCC HN4 cells derived from the tongue and
metastasized HNSCC HN12 cells derived from a lymph node, from the same patient. These cell
lines were chosen because HN4 cells express lower levels of EPS8, whereas, HN12 cells express
higher levels of EPS8 (14).

1.11 Hypothesis and Specific Aims
In the present study, we are investigating the role of Src signaling and its effects on EPS8
function. We hypothesize that activation of Src enhances EPS8 function and it deregulates
downstream signaling pathways, leading to increased cell proliferation. We have identified two
aims to investigate this hypothesis.
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For aim 1, we will determine the effect of Src inhibition on expression of EPS8 and its
regulated target genes, FOXM1, CXCL5, and Nanog. We will inhibit Src by using a small
molecule tyrosine kinase inhibitor, Dasatinib, in two HNSCC cell lines with different
phenotypes. We will also inhibit Src in spheroids to see if it has an effect on CSCs. We will
measure the expression of EPS8 and its target genes by using qRT-PCR and Western Blot.
Aim 2 will be focused on determining the effects of Src inhibition on the biological
functions of EPS8. In this aim, we will use WST-1 and cell counting to see whether cell
proliferation is effected by Src inhibition.

12

2. Materials and Methods

2.1 Cell lines and culture conditions
HN4 cells that are derived from a primary squamous cell carcinoma (14) and HN12 cells
from the same patient from a metastasized lymph node (14) were cultured in Dulbecco’s
Modified Eagle’s Medium (DMEM) (Gibco Life Technologies) supplemented with 10% fetal
bovine serum (FBS), 4.5 g/L D-Glucose, L-Glutamine, 110 mg/L sodium pyruvate, and 5 mL of
10,000U/mL of penicillin and 10,000μg/mL of streptomycin (Gibco Life Technologies). Cells
were incubated at 37 ̊C, 10% CO2, with a medium change every 2-3 days.
When cells reached 70-80 % confluency, the medium was aspirated and the plates were
washed 2x with 10mL of phosphate buffered saline (PBS) solution to remove any leftover
growth media. To disassociate the cells, 0.05% Trypsin-EDTA (Mediatech, Inc.) was added and
the plates were incubated for 10 minutes at 37 ̊C. Cells were resuspended in complete growth
medium to a total of 10mL. They were re-plated at 1:10 dilution for continued growth.
Cell stocks were created by transferring the cells to a 15mL centrifuge tube after
trypsinization, and centrifuging the cells at 800 rpm, for 5 minutes at 4 ̊C. The media was
aspirated off, and the cells were resuspended in 1mL of cold Bambanker (Wako Chemicals)
solution. 500 μL of the solution was added to two cryogenic vials (Corning) each and stored at 80 ̊C.

2.2 Spheroid Cultures
Cells were trypsinized as described above and placed in a 15mL centrifuge tube. A cell
count was done using an automatic cell counter (Cellometer Auto T4; Nexcelom Bioscience).
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Cells were resuspended in complete growth medium at a density of 1×106/ml. 20μL droplets of
cell susupension were placed on the inside of the lid of a 10cm plate, 60-70 droplets per lid. 2mL
of complete growth medium was added to the plate. The lid was inverted to allow the cells to
grow in suspension. They were incubated at 37 C
̊ , 10% CO2 for 48-72 hours.

2.3 RNA Isolation
Spheroids: Spheroids were recovered after 48 hours into a 1.5mL microcentrifuge tube
and centrifuged at 2,000rpm for 5 minutes. The medium was aspirated and 1 mL of TRIzol
reagent (Life Technologies) was added to the tube. The spheroids were pipetted to dissociate the
cells and placed on a rocker for 5 minutes at room temperature to homogenize the sample and
cause the complete dissociation of nucleoprotein complexes. 0.2mL of chloroform was added to
the tube. Monolayer: Cells with a cell count of 5×105 cells/mL were seeded in 2 wells of a 6well plate. The medium was aspirated after 48 hours and 1 mL of TRIzol was added to each well.
The plate was placed on a rocker for 5 minutes at room temperature. The contents were
transferred to 1.5mL microcentrifuge tubes containing 0.2mL chloroform. Subsequent steps for
spheroids and monolayer were identical. Tubes were then shaken vigorously for 15 seconds and
centrifuged at 12,000xg for 10 minutes at 4 ̊C to separate the phenol-chloroform phase from the
upper aqueous phase, which contained the RNA. The aqueous phase was transferred to a fresh
microcentrifuge tube containing 0.5 mL of isopropanol to precipitate the RNA from the aqueous
phase. The samples were inverted several times and incubated at room temperature for 10
minutes and centrifuged at 12,000xg for 10 minutes at 4 ̊C. The supernatant was removed and the
RNA pellet was washed once with 0.5mL of 75% ethanol. The tubes were centrifuged at
12,000xg for 10 minutes at 4 ̊C. The supernatant was removed and tubes were inverted to air dry
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the pellet. The RNA pellet was resuspended in 30μL of RNase-free water and stored at -80°C
until ready for use.
A spectrophotometer (Nanodrop; Thermo Scientific) and ND1000 software were used to
measure RNA concentration. The purity of isolated RNA was measured by using the 260/280
value of each sample. A value of 2.00 indicates pure RNA.

2.4 Reverse Transcription
1-5 μg of total RNA was added to a microfuge tube. The volume was made up to 11 μL
with RNase-free water. 1μL each of oligo(dT)18 (0.5μg/μL) (Sigma-Aldrich, Inc) and dNTP mix
(10mM each) (Takara Bio Company) was added to the microcentrifuge tube. Following a short
centrifugation, the samples were denatured at 65 C
̊ for 5 minutes and chilled on ice for 5
minutes. The samples were centrifuged again for a brief time. While being placed on ice, 2μL of
0.1M DTT (Gibco Life Technologies) and 4 μL of 5X First-Strand Reaction Buffer (Gibco Life
Technologies) were added to each tube. 1 μL of Multiscribe Reverse Transcriptase (50U/uL)
(Applied Biosystems) was added to each sample and mixed by stirring gently. The samples were
incubated at 42 ̊C for 50 minutes. The tubes were heated at 70 ̊C for 15 minutes to inactivate the
reverse transcriptase. The samples were stored at -20 ̊C until ready to use for qPCR experiment.

2.5 Quantitative Reverse Transcription PCR (qRT-PCR)
Total RNA was prepared, quantified, and reverse transcribed as described previously.
The following reagents were added to each well of a fast optical 96-well reaction plate (Applied
Biosystems): 5μL of 2X Blue qPCR SYBR low ROX (Thermoscientific), 3μL of RNase-free
water, and 1μL of primer mix. Oligonucleotide sequences of primers were acquired from Sigma15

Aldrich, Inc. (St. Louis, MO) and are listed in Table 1. A Master Mix was made containing the
aforementioned reagents for the total number of wells to be used and 9μL of the Master Mix was
added into each well. This was done to reduce the chance of error due to pipetting variability.
1μL of RNase-free water was added to one well per primer mix as a negative control with no
cDNA template. 1μL of template DNA was then added to triplicate wells. To generate relative
standard curves for each gene target, 1μL of serial dilutions of previously prepared PCR products
for each primer combination were also added to separate wells to act as standards. The plate was
sealed with optical adhesive film (Applied Biosystems) and centrifuged briefly to collect the
samples at the bottom. The plate was placed into the 7500 Fast Real-Time PCR System thermal
cycler (Applied Biosystems) and incubated at 50 ̊C for 2 minutes for 1 repetition, then 95 ̊C for
10 minutes for one repetition before cycling through 40 repetitions of 95 ̊C for 15 seconds and
60 ̊C for 1 minute. The software used for the qPCR experiment was 7500 Fast System Software.
Amplification of γ-tubulin (TubG) or GAPDH was performed for each reaction as a
housekeeping gene and used to normalize target gene expression within each sample. The mean
value of each primer’s triplicate sample wells was divided by the mean value of the
corresponding tubulin triplicate wells.
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Table 1. Oligonucleotide sequences for PCR
Gene

Target Sequence

EPS8 (Q1s)

5’-CAAAACAGCAGCTCCAGTGA

EPS8 (Q2s)

5’-TGAGATTTCCTTCGGTCCAC

FOXM1 (s)

5’-TTGCCCGAGCACTTGGAATC

FOXM1 (as)

5’-GTATGAGCTGACCCGTGGT

Nanog (s)

5’-TGATTTGTGGGCCTGAAGAAAA

Nanog (as)

5’-GAGGCATCTCAGCAGAAGACA

CXCL5 (Q1s)

5’-GTGTTGAGAGAGCTGCGTTG

CXCL5 (Q2s)

5’-CTATGGCGAACACTTGCAGA

AuroraB (Q1)

5’-GGGAGAGCTGAAGATTGCTG

AuroraB (Q2)

5’-GCACCACAGATCCACCTTCT

γ – tubulin (r)

5’-ACCAGCTTCTTAGGATACCTGT

γ – tubulin (f)

5’-AGAGGGCTTTGTGCTGTGTC

GAPDH (f)

5’-CTCTGCTCCTCCTGTTCGACA

GAPDH (r)

5’-ACGACCAAATCCGTTGACTC

2.6 Protein Isolation
Lysis buffer (20mM HEPES, pH 7.5; 10mM EGTA, pH 8.0; 8.64mg/mL g of βglycerophosphate; 1% of NP-40; and 2.5mM MgCl2) was supplemented with protease inhibitors
by adding 1μL 10 mg/mL aprotinin, 1μL 10mg/mL leupeptin, and 1μL 0.1M PMSF protease
inhibitor to 1mL lysis buffer.
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For monolayer cell lysate preparation, plates were washed with cold PBS, which was
aspirated thoroughly. 50μL of lysis buffer with protease inhibitors was added to each well of
sub-confluent cells grown in a 6 well plate. For 10-cm plates, 300μL of lysis buffer was added to
sub-confluent cells. The plates were left on ice for 10-15 minutes. The cells were scraped from
the plate and added to a microcentrifuge tube. For spheroid cell lysate preparation, the spheroids
were recovered after 48 hours into a 1.5mL microcentrifuge tube and centrifuged at 4 C
̊ for 10
minutes at 12,000xg. The medium was aspirated and 100μL of cold PBS was added to the
spheroids pellet. The cells were centrifuged again at 4 ̊C for 10 minutes at 12,000xg. The PBS
was carefully aspirated and 50μL of lysis buffer with protease inhibitors was added to the
microcentrifuge tube. The tubes were kept on ice for 10-15 minutes, with flicking of the tube
every 2-3 minutes to ensure the spheroids were coated properly with lysis buffer. Subsequent
steps for spheroids and monolayer were identical. The tubes were centrifuged for 10 minutes at
4 ̊C and 12,000xg for protein isolation. After centrifugation, the supernatant was transferred to a
fresh microcentrifuge tube and stored at -20 ̊C until ready for use.
For protein concentration determination, 795μL water (Millipore Corp.), 200μL of BioRad Protein Assay Dye Reagent Concentrate (Bio-Rad) and 5μL of protein sample were added to
a 1.5mL microcentrifuge tube and vortexed. The samples were transferred to a 1mL disposable
cuvette to determine the absorbance using the BioMate 3S Spectrophotometer (Thermo
Scientific). 5μL of lysis buffer with protease inhibitors was added instead of the protein sample
to set the blank. The protein concentration was quantified using a standard curve and equation,
generated using defined quantities of bovine serum albumin (BSA).
After the protein concentration for the samples was determined, the volume that
contained the same amount of protein was calculated for all of the remaining samples and the
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total volume was made up to the original volume with lysis buffer. 5X SDS sample buffer was
added to each sample for a final concentration of 1X. The samples were heated at 95 C
̊ for 5
minutes to denature the proteins. The samples were chilled on ice for 5 minutes.

2.7 Western Blot
Cell lysates were resolved on SDS-polyacrylamide gel in 1X SDS-PAGE running buffer
(25mM Tris-HCl, 250mM glycine, 0.1% SDS) for 1.5 hours at 120V constant voltage or until the
marker dye was near the bottom of the gel. The proteins were then transferred from the gel to a
PVDF transfer membrane (Immobilon-P; Millipore Corp.) overnight in 1X transfer buffer
(25mM Tris-HCl, 192mM glycine, 10% MeOH) at 5mA constant current. Prior to transfer, the
membrane was soaked in transfer buffer for 5 minutes. After the transfer, the membrane was
placed in 100% methanol to fix the proteins. The membrane was then dried completely, re-wet in
100% methanol and rehydrated in Tris-Buffered Saline with Tween 20 (TTBS) for 5 minutes.
The membrane was incubated in blocking buffer (5% non-fat dried milk in TTBS) for 1-4
hours on a shaker at room temperature. It was incubated overnight at 4 ̊C with the primary
antibody diluted in 5% blocking buffer (Table 2). The membrane was washed three times with
TTBS and incubated for one hour in secondary horseradish peroxidase-conjugated (HRP)
antibody diluted in 5% blocking buffer (Table 2). The membrane was washed again three times
in TTBS. The proteins were detected using Western Lightning Plus-ECL Oxidizing Reagent and
Western Lightning Plus-ECL Enhanced Luminol Reagent (PerkinElmer Inc.) and imaged onto
Blue Basic Autoradiography film (GeneMate; BioExpress) using an OPTIMAX X-Ray Film
Processor. The membrane was then washed with TTBS three times and re-probed for β-actin or
GAPDH to ensure that equal amounts of protein were loaded for each sample.
19

Table 2. Antibodies for Western Blot.
Secondary horseradish peroxidase-conjugated (HRP) antibody for all was diluted 1:10,000,
except for FOXM1, which was diluted 1:5,000.
Primary Antibody

Dilution

Secondary Antibody Company

EPS8

1:1000

Anti-Mouse

BD Biosciences

1:1000

Anti-Rabbit

Cell Signaling

(610144)
Aurora B/AIM1
(3094)
FAK (D2R2E)

Technology
1:1000

Anti-Rabbit

(13009)
FOXM1 (C-20)

Technology
1:1000

Anti-Rabbit

(Sc-502)
P-FAK (Y576/577)

1:1000

Anti-Rabbit

1:1000

Anti-Rabbit

Cell Signaling
Technology

1:1000

Anti-Goat

(Sc-1616)
GAPDH (14C10)

Cell Signaling
Technology

(3580)
β-Actin (I-19)

Santa Cruz
Biotechnology Inc.

(3281)
Nanog

Cell Signaling

Santa Cruz
Biotechnology Inc.

1:1000

Anti-Rabbit

(2118)

Cell Signaling
Technology

2.8 Cell Proliferation
To determine proliferation, 6×103 HN12 cells were plated in quadruplicate in 24-well cell
culture plates. After allowing the cells to attach overnight, 300nM of Dasatinib (LC
Laboratories), or an equal volume of DMSO as control, was added to the wells. The cells were
washed with PBS, trypsinized, and counted daily for 7 consecutive days using a cell counter.
Phase contrast images of the cells were also acquired on each day.
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2.9 WST-1 Assay
To determine cell viability, HN12 cells were plated in a 96-well cell culture plate. The
number of cells seeded per well was determined based on how long the assay would continue.
200μL of medium was added to the wells and the cells were allowed to attach overnight. The
following day, 300nM of Dasatinib, or an equivalent volume of DMSO, was added to the wells.
Every 24 hours, 100μL of fresh media was added to each well and 10μL of WST-1 Reagent
(Roche) was also added to each well. The plate was incubated in 37 ̊C, 10% CO2 for 30 minutes
to 1 hour, depending on when the medium changed color. The results were then quantified using
a microplate spectrophotometer (Epoch; Bio-Tek).

2.10 Cell Cycle Analysis: Flow Cytometry
Cell were seeded in a 10cm plate, with the density depending on the length of the
treatment, and allowed to attach overnight. The next day, cells were treated with 300nM of
Dasatinib or an equivalent volume of DMSO for 24 hours or 48 hours. To fix the cells, the
medium was collected from the culture plate and stored in a 15mL centrifuge tube. The cells
were trypsinised and collected using the previously stored medium. Cells were centrifuged at
4°C, 288×g, for 10 minutes and resuspended in 10mL of ice-cold PBS. Another PBS wash
followed at 4°C, 288×g, for 10 minutes. The pellet was resuspended in 5 mL of ice-cold 80%
ethanol, which had been stored at -20°C. Cells were fixed overnight at 4°C.
After fixation, cells were centrifuged at 4°C, 288×g, for 10 minutes, resuspended in 1mL
of PBS and transferred to a microcentrifuge tube. Cells were centrifuged at room temperature for
5 minutes at 2000×g. Cells were resuspended in PBS with 100μg/mL (DNase)-free RNase A and
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50μg/mL of propidium iodide (PI). The cells were stained for 30 minutes at 37°C. The cells were
analyzed by Guava easyCyte flow cytometer.

2.11 Statistical Analysis
Data were analyzed by unpaired t-test to compare two means using GraphPad QuickCalcs
software (http://www.graphpad.com/quickcalcs). A p-value less than 0.05 was considered
statistically significant.
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3. Results

3.1 Potential cancer stem cell markers expression in HN4 cells
We tested for expression of potential CSC makers in HN4 cells by flow cytometry. By
looking at previous studies investigating CSC markers in tumors, we decided to test for the
following markers: CD44, CD326, CD26, CD24. We were able to get two separate cell
populations, CD326high and CD326low, with all of the cells testing positive for CD44. All cells
tested negative for CD26. We were able to get CD24high and CD24low sorting initially, with the
populations being lost to diminished labeling by the PE antibody. To determine the tumorigenic
potential of CD326high and CD326low cells, we tested for EPS8 and FOXM1 expression. Figure 1
shows expression of EPS8 and FOXM1 is slightly higher in CD326high cells compared to
CD326low cells, although not significant.
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Figure 1. HN4 cells sorted for cell markers CD326high and CD326low.
A-B) HN4 cells sorted for potential stem cell markers CD326high and CD326low were tested for
expression of FOXM1 and EPS8. GAPDH levels were measured as a control. B) Relative
expression of FOXM1 and EPS8 bands normalized to GAPDH.

For protein extraction, cells were seeded at the same density. Images of the cells were
taken after 24 hours (Day 1) and 48 hours (Day 2) as shown in Figure 2. There appears to be a
difference in cell morphology between the two sorted cell lines and CD326high cells are less
likely to form colonies.
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Figure 2. HN4 CD326high and CD326low cells at different time points.
HN4 cells sorted for potential stem cell markers CD326high (CD326H) and CD326low (CD326L)
were photographed at 24 hours (A) and 48 hours (B) after cell seeding at the same density.
Original magnification ×50, ×100, or ×200. Scale bar indicates 200 μm.
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3.2 EPS8 expression is increased in spheroids
Spheroids have previously been described as having a cancer stem cell phenotype (5). We
used the spheroid colony formation method in our experiments. HN4 cells, which are primary
tumor-derived cells, were plated on the lid of a 10cm plate at a density of 2×104 cells/mL. The
lid was flipped over to allow the cells to grow in suspension. Since EPS8 expression was shown
to be higher in HN12 cells, which are derived from a lymph node metastasis, compared to HN4
cells (14) we wanted to determine the protein levels of EPS8 in HN4 spheroids by western
blotting. As shown in Figure 3, EPS8 expression is higher in spheroids compared to the HN4
cells grown in an adherent, monolayer culture. The actin bands are shown as a loading control
for both samples to assure the differences are due to changes in protein level expression and not
by differences in sample loading.
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HN4 Spheroid
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Figure 3. HN4 cells set up as spheroids show higher expression of EPS8
A-B) HN4 cells seeded in a monolayer culture and spheroid culture were tested for expression of
EPS8. EPS8 levels were higher for the spheroid culture compared to the monolayer culture. βactin levels were measured as a control. B) Relative expression of EPS8 bands normalized to βactin.
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3.3 Expression of downstream targets of EPS8 in spheroids
Since spheroids have higher protein levels for EPS8, we decided to check the expression
levels of EPS8 and its downstream targets, which include FOXM1, CXCL5, and Nanog. We
isolated RNA from HN4 monolayer cells and HN4 spheroids, and analyzed the cDNA product
by qRT-PCR, using either γ-Tubulin or GAPDH as housekeeping genes to normalize the results.
Figure 4 shows that expression of EPS8, FOXM1, CXCL5, and Nanog is increased in spheroids,
as we had originally predicted.

A)

B)

p = 0.0107
p = 0.0006

D)

C)

p = 0.0140
p = 0.0026

Figure 4. HN4 cells set up as spheroids show higher expression of EPS8 and its downstream
targets.
A-D) Expression of EPS8, FOXM1, Nanog, and CXCL5 mRNA in HN4 cells as measured by
qRT-PCR, normalized to γ-Tubulin as a standard. Data are representative of at least two
independent experiments.
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3.4 Src inhibition lowers EPS8 expression in spheroids
Since we found that spheroids have higher expression of EPS8 and potential stem cell
like properties, we wanted to test for EPS8 levels in spheroids after treatment with 300nM of
Dasatinib for 48 hours. First, we wanted to make sure DMSO was a proper solvent that did not
affect protein expression. We tested for EPS8 expression in HN4 spheroids and HN4 spheroids
treated with DMSO. Figure 5 shows that DMSO did not affect protein expression. Spheroids
were treated for 48 hours as that is the ample time needed for them to grow in suspension. By
western blot, we found that expression of EPS8 was lower in Dasatinib treated spheroids (Figure
6).
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Figure 5. Testing DMSO as a control
A-B) HN4 spheroids were treated with DMSO for 48 hours. Treatment with DMSO did not
affect EPS8 protein levels. GAPDH levels were measured as a control. B) Relative expression of
EPS8 bands normalized to GAPDH.
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Figure 6. HN4 spheroids treated with Dasatinib.
A-B) HN4 cells set up as spheroids treated with 300nM of Dasatinib or an equivalent volume of
DMSO as a control for 48 hours. β-actin levels were measured as a control. B) Relative
expression of EPS8 bands normalized to β-actin.
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The spheroids that were treated with Dasatinib did not form a tight cluster of cells as did
DMSO treated cells. There were more cells in the periphery of the Dasatinib treated spheroids
and the marginal rims were not as evident (Figure 7).

Figure 7. Images of HN4 spheroids treated with Dasatinib.
HN4 cells set up as spheroids treated with 300nM of Dasatinib or an equivalent volume of
DMSO as a control for 48 hours. Images were taken 48 hours after cell seeding. Scale bar
indicates 200 μm.
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FAK protein levels for HN4 spheroids treated with Dasatinib were also measured. Figure
8 shows a decrease in FAK protein levels, similar to the trend seen in EPS8 protein levels.
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Figure 8. FAK protein levels from HN4 spheroids treated with Dasatinib.
A-B) HN4 cells set up as spheroids treated with 300nM of Dasatinib or an equivalent volume of
DMSO as a control for 48 hours. FAK protein levels were measured by western blot and they
decreased similar to EPS8 protein levels. GAPDH protein levels were measured as a control. B)
Relative expression of FAK and EPS8 bands normalized to GAPDH.
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3.5 Src inhibition in HN12 cells
Since HN12 cells have a more tumorgenic phenotype, we wanted to determine the effects
of Src inhibition on these cells. We seeded HN12 cells in a 6 well plate and allowed them to
attach overnight. After letting them attach, we added either 300nM of Dasatinib or an equivalent
volume of DMSO to the medium as a control. The cells were treated for 24 hours with the drug
before isolating for protein or RNA. First, we wanted to see if the cells were still viable after 24
hours; therefore, we checked cell viability using the WST-1 Assay. Figure 9 shows the cells were
58% viable after 24 hours treatment with Dasatinib.
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Figure 9. HN12 cell viability after Dasatinib treatment for 24 hours.
HN12 cells were treated with 300nM of Dasatinib or an equivalent volume of DMSO as a
control for 24 hours. Cell viability was measured after 24 hours using a WST-1 Assay. Data are
representative of at least three independent experiments. (Bar = S.E.M)
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Next, we checked for EPS8 protein levels in HN12 cells treated with Dasatinib by
western blot. As shown in Figure 10, EPS8 levels were reduced for Dasatinib treated cells.
Because EPS8 protein levels decreased, we checked for protein levels of FOXM1 to see if they
had a similar result. FOXM1 protein levels also decreased and very faint bands were visible for
Dasatinib treated HN12 cells compared to the control (Figure 11).
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Figure 10. HN12 cells treated with Dasatinib.
A-B) HN12 cells seeded in a monolayer culture treated with 300nM of Dasatinib or an
equivalent volume of DMSO as a control for 24 hours. GAPDH levels were measured as a
control. B) Relative expression of EPS8 bands normalized to GAPDH.
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Figure 11. FOXM1 protein levels in HN12 cells treated with Dasatinib.
A-B) HN12 cells seeded in a monolayer culture treated with 300nM of Dasatinib or an
equivalent volume of DMSO as a control for 24 hours. GAPDH levels were measured as a
control. B) Relative expression of FOXM1 bands normalized to GAPDH.

We then used qRT-PCR to check for EPS8, FOXM1, and Nanog expression levels when
HN12 cells were treated with Dasatinib. Figure 12 shows that expression of EPS8 and FOXM1
decreased when Src was inhibited by Dasatinib. This is in agreement with our hypothesis that Src
activation deregulates downstream signaling pathways of EPS8. However, expression of Nanog
increased when HN12 cells were treated with Dasatinib.
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Figure 12. HN12 cells show lower expression of EPS8 and FOXM1 when treated with
Dasatinib.
HN12 cells seeded in a monolayer culture treated with 300nM of Dasatinib or an equivalent
volume of DMSO as a control for 24 hours. A-B) Expression of EPS8, FOXM1 mRNA in HN12
cells is decreased. C) Expression of Nanog mRNA in HN12 cells is increased. It is measured by
qRT-PCR and normalized to GAPDH as a standard. Data are representative of at least three
independent experiments.

35

3.6 Src inhibition decreases the proliferation rate of HN12 cells
EPS8 has been previously shown to increase cell proliferation; therefore, to see if
Dasatinib influences cell proliferation rates, a proliferation assay was carried out. HN12 cells
were seeded at a density of 6×103 cells per well in quadruplicate and cultured for seven days.
Dasatinib was added to the medium after letting the cells attach overnight. The cell number was
determined by counting at 24 hour intervals from Day 1 through Day 7. We found that the cell
number for Dasatinib treated cells did not increase exponentially as did the cell number for
control treated cells, shown in Figure 13.
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Figure 13. Effect of Dasatinib on cell proliferation in HN12 cells.
HN12 cells were plated in quadruplicate and treated with 300nM of Dasatinib or an equivalent
volume of DMSO as control. Cells were trypsinized and counted daily for 7 days. Data are
representative of at least three independent experiments. (Bar = S.E.M)
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To confirm these results, cell viability was determined using the WST-1 assay. Cells
were plated in multiplicate in 96-well plates and treated with Dasatinib. Cell viability was
measured at 24 hour intervals from Day 1 through Day 7 by adding WST-1 reagent, incubating
for 30 minutes, and measuring the absorbance at 450 and 650 nm. Dasatinib treated cells became
less viable as treatment proceeded, while control treated cells remained completely viable
throughout the 7-day treatment, as shown in Figure 14.
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Figure 14. HN12 cell viability after Dasatinib treatment for 7 days.
HN12 cells were treated with 300nM of Dasatinib or an equivalent volume of DMSO as a
control for 7 days. Cell viability was measured every 24 hours for 7 days using a WST-1 Assay.
(Bar = S.E.M)
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3.7 Src inhibition leads to cell morphology changes
Figure 15 shows images of Dasatinib and DMSO treated HN12 cells over a course of 7
days. Dasatinib starts affecting HN12 cells as early as Day 1. Dasatinib induces a change in cell
morphology, with Dasatinib treated cells having more of an arborized and contracted appearance.
With longer treatment, the changes are more evident. The cells have a slower rate of proliferation
for Dasatinib treated cells and they are less likely to form colonies. By Day 4 and Day 5 in with
treatment, it is difficult to differentiate between the individual cells. It is not clear whether the
cells are completing cytokinesis and forming distinct cells or forming a multinuclear cell.
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Figure 15. Effect of Dasatinib on cell morphology and cell proliferation in HN12 cells.
HN12 cells were treated with 300nM of Dasatinib or an equivalent volume of DMSO as a
control for 7 days. A) Original magnification x100. B) Original magnification x200. Scale bar
indicates 200 μm.
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3.8 Decreased expression of FOXM1 induces cell cycle arrest in HN12 cells
FOXM1 is an important cell cycle regulator, and Dasatinib decreases the expression of
FOXM1 as we previously showed. We wanted to examine whether the cells were not
proliferating due to cell cycle arrest from decreased FOXM1 expression. We used a
fluorescence-activated cell sorter for cell cycle analysis. As shown in Figure 16, analysis of
HN12 cells treated with Dasatinib for 24 hours indicated an increase in the percentage of cells in
G1 and a decrease in the S and G2/M population of cells compared with the DMSO control
group.
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Figure 16. Effect of Dasatinib on the cell cycle in HN12 cells.
HN12 cells were treated with 300nM of Dasatinib or an equivalent volume of DMSO as a
control for 24 hours. The cells were fixed and stained with propidium iodide and their DNA
content was analyzed.
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Since FOXM1 is a transcription factor that is responsible for the transcription of many
proteins involved in the cell cycle, we tested for the expression of Aurora B kinase, a
downstream target of FOXM1. We checked for the expression of Aurora B kinase in HN12 cells
treated with Dasatinib by using qPCR. As shown in Figure 17, mRNA expression of Aurora B
kinase was lower in HN12 cells treated with Dasatinib. Next, we checked protein levels for
Aurora B kinase in HN12 cells by using western blotting. Just as expected, Aurora B kinase
protein expression was lower in Dasatinib treated cells, similar to FOXM1 protein levels.
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Figure 17. Effect of Dasatinib on Aurora B expression in HN12 cells.
HN12 cells were treated with 300nM of Dasatinib or an equivalent volume of DMSO as a
control for 24 hours. A) Expression of Aurora B mRNA in HN12 cells as measured by qRTPCR, normalized to GAPDH as a standard. Data are representative of at least two independent
experiments. B) Treatment with Dasatinib decreased Aurora B protein levels. GAPDH levels
were measured as a control. C) Relative expression of FOXM1 and Aurora B bands normalized
to GAPDH.
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3.9 Phosphorylation of FAK may be a key determinant of turnover rate.
We originally measured the protein levels of FAK and Phospho-FAK (Tyr576/577) to
check if Dasatinib was working properly by inhibiting Src. We found that when cells were
treated with Dasatinib and the phosphorylation of FAK by Src was inhibited, it led to the
decrease in focal adhesion kinase turnover. Figure 18A shows protein levels of FAK when
treated with Dasatinib in HN12 cells. Figure 18B shows protein levels of Phospho-FAK when
treated with Dasatinib and there are evident bands for Phospho-FAK at different weights in
control cells which are absent or reduced density in Dasatinib treated cells, suggesting that Srcmediated phosphorylation plays a key role in FAK proteolysis.
A)

B)

P‐FAK 125 kDa

FAK 125 kDa

GAPDH

GAPDH

Figure 18. Effect of Dasatinib on FAK and P-FAK expression in HN12 cells
HN12 cells were treated with 300nM of Dasatinib or an equivalent volume of DMSO as a
control for 24 hours. A) This shows protein levels of P-FAK (Tyr 576/577) in HN12 cells after
being treated with Dasatinib for 24 hours. B) This shows protein levels of FAK in HN12 cells
after being treated with Dasatinib for 24 hours. A longer exposure of the WB is shown here to
illustrate the full effect of Dasatinib on FAK turnover.
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4. Discussion

4.1 Spheroids exhibit a cancer stem cell phenotype
The cancer stem cell hypothesis that has been proposed in recent years provides a rational
explanation for tumor initiation and tumor recurrence (5,6). Squamospheres, or spheroids, have
been of particular interest in our lab to see if they exhibit cancer stem cell properties. In our
present study, we used HN4 cells, as they have a less tumorigenic phenotype, to set up spheroids.
Previously, EPS8 overexpression has been shown to lead to increased proliferation and migration
of primary tumor cells, both of which are properties important for tumor development and
progression (14). Since EPS8 levels are low in HN4 cells set up in a monolayer culture, we
wanted to determine if HN4 spheroids had higher expression of EPS8. When comparing protein
levels of EPS8 for HN4 cells set up as a monolayer and HN4 cells set up as spheroids, EPS8
levels were higher in spheroids, suggesting that spheroids perhaps facilitate tumor development.
Therefore we decided to check for the downstream mediators of EPS8. EPS8, FOXM1, Nanog,
and CXCL5 are known to lead to tumor progression, so we used qRT-PCR to measure their
expression in both HN4 monolayer cells and HN4 cells set up as spheroids. Expression for all
them was increased in spheroids, leading us to believe that spheroids possess more stem cell
characteristics than HN4 cells set up in a monolayer culture.
Many cell surface markers for CSCs have been identified for other cancers; therefore, we
wanted to identify cell surface markers for HNSCC that could potentially help us identify CSCs.
CD44 is a putative stem cell marker for HNSCC (12); therefore, we decided to stain for it in
HN4 cells and all cells showed up positive for CD44. Although previous studies have indicated
that CD44 may be a CSC marker, it is unlikely that all cells in this population are CSCs;
therefore, the utility of CD44 as a CSC marker is unreliable for our population of HN4 cells. A
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previous study has shown that 60%-90% of normal epithelia express CD44 (6). While CD44
might indeed be a known CSC marker for HNSCC, by itself it is not a sufficient marker to
isolate CSCs. We were also able to get separate populations for CD326, with CD326high and
CD326low cells. To determine which cell population contains potential CSCs, we used western
blot to measure protein levels for EPS8 and FOXM1. There were no significant differences in
FOXM1 and EPS8 expression between CD326high cells and CD326low cells. Perhaps the
combination of CD44, CD326 and other markers may be necessary to define a CSC population.
Some additional studies need to be performed with the different sorted cell populations to
determine their CSC profile. Cell proliferation assays can be done in the future to check
proliferation rates for both cell types. To check cell migration, a wound-healing (Scratch) assay
can also be performed. To further check their CSC profile, spheroids should be seeded using the
different CD326-expressing cell populations to check which populations are able to grow in
suspension.

4.2 Src inhibition in HN4 spheroids
Previous studies have examined the role that Src inhibition by Dasatinib plays on cell
proliferation and cell survival (36), however, there is no conclusive result for what effect
Dasatinib has on cells grown in suspension from a primary HNSCC cell line. We predicted that
cells treated with Dasatinib would not form spheroids similar to spheroids formed by control
cells. In this study, we found that HN4 cells set up as spheroids had higher expression of EPS8
and its downstream targets, raising the possibility that they contain CSCs.
We treated our spheroids with 300nM of Dasatinib to see the effects of Src inhibition on
the formation of spheroids and cell signaling. Just as we had hypothesized, spheroids treated with
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300nM of Dasatinib did not form a tight cluster of cells as the control cells did. We found that
protein levels for FAK were lower when Src was inhibited by Dasatinib. It has been shown
previously that FAK gives survival signaling and suppresses apoptosis (37). Src-mediated
phosphorylation of FAK promotes cell survival and anchorage-independent growth of
transformed cells by involving signaling cascades that likely involves PI3K/AKT, which has
been identified as a downstream mediator of both Src and FAK and also EPS8 (14, 37). With
lower levels of FAK and other related signaling molecules, perhaps that causes some cells to
undergo apoptosis. We also found EPS8 levels to be lower for Dasatinib-treated spheroids. Src
activation may play a role in activating EPS8 and increasing its expression in HN4 cells.

4.3 Src inhibition in HN12 cells
Previous studies done with Dasatinib using HNSCC cell lines have shown that Dasatinib
has antitumor effects (38), so we wanted to investigate further the effects Src inhibition has on
HN12 cells.
When HN12 cells were treated with 300nM of Dasatinib for 24 hours, more than 50% of
cells were still viable. We wanted to perform a longer experiment and see what effect Dasatinib
had on cell proliferation and cell viability. We found that cell viability decreased for Dasatinib
treated cells and the cells were not proliferating. Since EPS8 has previously been shown to
increase cell proliferation (14), we checked for protein levels of EPS8. EPS8 levels for Dasatinib
treated HN12 cells were slightly lower compared to the control, although not significant. Since
the difference was not significant, we checked for EPS8 mRNA levels and no significant
difference was found either.
Cell morphology also changed when cells were treated with Dasatinib. It was not clear
whether cells were undergoing apoptosis or cell cycle arrest. To address this, we checked protein
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levels of FOXM1, which is a key cell cycle regulator and also a downstream mediator of EPS8.
FOXM1 protein levels were greatly diminished in cells treated with Dasatinib. We also checked
for FOXM1 mRNA levels and found a similar result. To further investigate this, we checked for
Aurora B kinase protein and mRNA levels. Aurora B is a downstream target of FOXM1 that is
important for chromosome segregation and cytokinesis (25). Aurora B mRNA and protein levels
were decreased in HN12 cells treated with Dasatinib. Our results suggest that Dasatinib might
induce cell cycle arrest in HN12 cells by decreasing levels of FOXM1 and Aurora B, which are
both important for progression of the cell cycle and completion of mitosis. We performed cell
cycle analysis after 24 hours of treatment and found increased numbers of cells in G0/G1 phase,
suggesting that there is cell cycle blockade in the transition from G1-S. The percentage of cells in
the G2/M phase still remain quite high, which can possibly be explained by the fact that FOXM1
is also an important regulator of the G2/M phase and it is required for the execution of the mitotic
program (23). This suggests that perhaps there is also an arrest in the G2 phase and the cells are
not completing mitosis.
When we measured mRNA levels for Nanog, we found that expression actually increased
in cells treated with Dasatinib. The cells are perhaps responding to a cytotoxic drug and up
regulating Nanog to self-renew. We need to perform additional studies to further investigate this
result.
We originally measured levels of P-FAK and FAK to check if Src was being inhibited by
Dasatinib. We found additional bands in the control cells that were of different weight. One
possibility for this is that Src-mediated phosphorylation plays a key role in FAK proteolysis. A
previous study has shown that v-Src mediated phosphorylation of FAK may be a necessary step
for FAK cleavage by calpain (37).
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Cancer stem cells are thought to be potential mediators of the drug resistance phenotype
of tumors and are thought to be responsible for the recurrence of tumors and resistance to
therapy. When EPS8 is overexpressed, it is shown to have increased drug resistance in HeLa
cells (39). By targeting EPS8 and its downstream signaling pathways, our study proposes a
strategy for future cancer therapy that targets cells that have increased drug resistance, lowering
the chance for tumor recurrence.

4.4 Limitations of the Current Study
There are limitations to the current study that should be considered. Since the cells are
grown in vitro in culture, they are not exposed to all of the mechanisms that are occurring in the
body. The temperature and humidity of the environment in which the cells were grown was
controlled to best attempt to adopt body conditions. Even though the best possible conditions
were used to culture the cells, in vivo experiments need to be carried out to complement the
results we have found so far.
When working with the WST-1 assay, it was difficult to make sure each well had the
exact amount of cells since we were dealing with such a small number of cells. This could have
possibly caused some of the wells to have skewed results. This is why we plated our cells in
multiplicate to reduce the chance of error.
The cell counting assay done to measure cell proliferation could also be a limitation for
this study. It is very difficult to ensure all wells have exactly the same amount of cells, giving
some variability with cell numbers. This is why we set up the wells in quadruplicate and
averaged the cell numbers and also performed the experiment multiple times. When trypsinizing
the cells to detach them from the plate, some cells could have been left behind on the plate.
Another limitation could have been using the Cellometer and cell counting program, which is
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generally concentration dependent. Since we resuspended our cells in a small volume, there is a
possibility that the cells were not resuspended properly and the concentration of the cells given
by the machine was inaccurate.
Since spheroids are clusters of cells that grow in suspension, it is possible that formation
of spheroids could have been disturbed. The cells had to be incubated and opening and closing of
the incubator could possibly disrupt the formation.

4.5 Future Studies
There are still many in vitro studies that can be completed to further complement our
results. Since we did not get conclusive results with CD44 positive and CD326 cells, additional
cell surface markers should be sorted for to isolate potential CSCs. Spheroids should be grown
for a longer time frame, rather than only 48 hours, so they can have longer treatment with
Dasatinib. This might help provide conclusive results for mRNA studies. Invasion and migration
studies should also be done with CD326high and CD326low cells so we can better determine which
one is better for isolating CSCs. Invasion and migration studies should also be performed with
Dasatinib treated cells to see what effect Src inhibition has on cell migration and cell invasion.
Ultimately, in vivo studies should be performed in animals to better complement our results.
Spheroids can be transplanted in mice to see if they lead to tumor progression and subsequently
treated with Dasatinib to see if they halt tumor progression and tumor recurrence.

4.6 Conclusions
This study indicates that Src plays a role in the proliferation of head and neck squamous
cell carcinoma cells, possibly through EPS8 and downstream target FOXM1. We found that
when Src was inhibited in spheroids from HN4 cells, the expression of EPS8 and FOXM1
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decreased. When Src was inhibited in HN12 cells, the proliferation was reduced due to lower
FOXM1 levels and Aurora B kinase levels, which are both important regulators of the cell cycle.
Figure 19 shows the possible relationship between Src and EPS8 and its downstream targets. The
results we found support our hypothesis that activation of Src enhances EPS8 function and it
deregulates downstream signaling pathway; however, further studies need to be performed to
fully understand the relationship between Src and EPS8.
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Figure 19. Possible interactions between Src, EPS8, and downstream targets of EPS8
leading to metastasis and migration.
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